• Home
  1. Home
  2. Nouveaux traitements de l'hépatite C : quelles cibles, quel calendrier?
Scientific article
French

Nouveaux traitements de l'hépatite C : quelles cibles, quel calendrier?

Contributors

Goossens, Nicolas; Negro, Francesco

Published in

Revue médicale suisse, vol. 7, no. 307, p. 1683-1688

Publication date

2011

Abstract

The hepatitis C virus (HCV) is a global major health burden, its response to current treatment is unfortunately inadequate, in particular for genotype 1. Two new direct acting antivirals, that inhibit NS3/4A viral protease, will soon be available on the Swiss market: telaprevir and boceprevir. These substances increase the rate of sustained viral response, in HCV genotype 1 infected patients, when coadministered with pegylated interferon and ribavirin. However, these new molecules may lead to serious adverse effects and drug interactions with which the specialist and the primary care physician must be familiar.

Keywords

  • Antiviral Agents/therapeutic use
  • Hepatitis C/drug therapy
  • Humans
  • Oligopeptides/therapeutic use
  • Proline/analogs & derivatives/therapeutic use

UNIGE affiliation entities

UNIGE research groups

Citation (ISO format)

GOOSSENS, Nicolas, NEGRO, Francesco. Nouveaux traitements de l’hépatite C : quelles cibles, quel calendrier? In: Revue médicale suisse, 2011, vol. 7, n° 307, p. 1683–1688.

Main files (1)

Article (Published version)

Identifiers

Additional URL for this publication

http://rms.medhyg.ch/numero-307-page-1683.htm

Journal ISSN

1660-9379
541views
0downloads

Technical informations

Creation

05/11/2012 10:10:00

First validation

05/11/2012 10:10:00

Update

14/03/2023 19:57:11

Status update

14/03/2023 19:57:11

Last indexation

30/10/2024 08:27:07
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated